NICE approves immunotherapy combination for advanced melanoma.
作者信息
Wise Jacqui
机构信息
London.
出版信息
BMJ. 2016 Jun 17;353:i3421. doi: 10.1136/bmj.i3421.
PMID:27317590
Abstract
摘要
相似文献
1
NICE approves immunotherapy combination for advanced melanoma.
BMJ. 2016 Jun 17;353:i3421. doi: 10.1136/bmj.i3421.
2
Adoption of ipilimumab in the United States: a Medicare study.
Expert Rev Pharmacoecon Outcomes Res. 2016 Aug;16(4):439-40. doi: 10.1080/14737167.2016.1180979. Epub 2016 May 3.
3
Strategies for individualizing management of patients with metastatic melanoma: a managed care perspective.
Am J Manag Care. 2015 Sep;21(10 Suppl):S234-41.
4
Combination Immunotherapy for Melanoma.
JAMA Oncol. 2015 Jun;1(3):387-8. doi: 10.1001/jamaoncol.2015.0479.
5
Melanoma treatment's changing landscape.
J Natl Cancer Inst. 2014 Jun 6;106(6):dju176. doi: 10.1093/jnci/dju176. Print 2014 Jun.
6
[New hope in metastatic melanoma treatment?].
Ann Dermatol Venereol. 2012 Oct;139(10):693-4. doi: 10.1016/j.annder.2012.05.030. Epub 2012 Sep 8.
7
Nivolumab plus ipilimumab in the treatment of advanced melanoma.
J Hematol Oncol. 2015 Oct 31;8:123. doi: 10.1186/s13045-015-0219-0.
8
Combined immunotherapy improves survival in metastatic melanoma.
BMJ. 2015 Jun 1;350:h2993. doi: 10.1136/bmj.h2993.
9
FDA approves new treatment of metastatic melanoma.
Cancer. 2016 Apr 15;122(8):1149. doi: 10.1002/cncr.29998.
10
Highlights from the ASCO annual meeting.
Cancer. 2013 Sep 1;119(17):3104-5. doi: 10.1002/cncr.28315.
引用本文的文献
1
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
Zotero 插件